Effectiveness of 3-week intervention of Shi Quan da Bu Tang for alleviating hematotoxicity among patients with breast carcinoma receiving chemotherapy

Integrative Cancer Therapies

Volumn 12, Issue 2, 2013, Pages 136-144

  Tai, Chen Jei ^c,d   Huang, Sheng Miauh ^a,b   Chien, Li Yin ^b   Tai, Cheng Jeng ^c,d   Chiou, Jeng Fong ^c,d   Chen, Ching Shyang ^c  

^a MACKAY MEDICAL COLLEGE   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast carcinoma; Chemotherapy; Hematotoxicity; Herbal formula; Shi Quan Da Bu Tang

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; SHI QUAN DA BU TANG;

ADULT; AGE; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG STRUCTURE; FEMALE; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERVENTION STUDY; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; STRUCTURED QUESTIONNAIRE; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; DRUG-INDUCED LIVER INJURY; DRUGS, CHINESE HERBAL; FEMALE; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84877811592     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735412450513     Document Type: Article

References (30)

1. Department of Health, Executive Yuan, Taiwan. The mortality of cancer in Taiwan. http://www.doh.gov.tw/CHT2006/DM/DM2-2-p02.aspx?class-no=440&now- fod-list-no=11397&level-no=4&doc-no=76512. Updated 2007. Accessed November 15, 2010.
2. US Cancer Statistics Working Group. United States Cancer Statistics: 2002-2006 Incidence and Mortality Web-based Report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. http://apps.nccd.cdc.gov. Updated 2010. Accessed November 15, 2010.
3. Fan Y, Xu B, Yuan P, et al. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Chemotherapy. 2010;56: 340-347.
4. Takabatake D, Taira N, Hara F, et al. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. Jpn J Clin Oncol. 2009;39: 478-483.
5. Fountzilas G, Athanassiades A, Papadimitriou V, et al. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Oncology (Williston Park). 1998;12(1 suppl 1):S45-S48.
6. Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist. 2004;9: 25-32.
7. Fortner BV, Houts AC, Schwartzberg LS. A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Support Oncol. 2006;4: 472-478.
8. McDermott CL, Blough DK, Fedorenko CR, et al. Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer. 2012;20:65-73. doi:10.1007/s00520-010-1055-y.
9. Lin YH, Chen KK, Chiu JH. Prevalence, patterns, and costs of Chinese medicine use among prostate cancer patients: a population-based study in Taiwan. Integr Cancer Ther. 2010;9: 16-23.
10. Shi HZ, Chiu HC, Ker CG, Chen YF, Huang YS. Utilization of medical resources by cancer patients from the Chi-Ching District in Kaohsiung. Formosa J Healthcare Admin. 2005;1: 67-75.
11. Ting HH, Huang CC, Chiu HL, Wu CT, Chou CC, Hou YC. Utilizations of complementary and alternative medicine in breast cancer patients: survey of a regional hospital surgery outpatient department. Chin J Integrated Chin Western Med. 2007;9: 7-13.
12. Yang C, Chien LY, Tai CJ. Use of complementary and alternative medicine among patients with cancer receiving outpatient chemotherapy in Taiwan. J Altern Complement Med. 2008;14: 413-416.
13. Ernst E, Schmidt K, Baum M. Complementary/alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology. Breast J. 2006;12: 526-530.
14. Wu Y, Zhang Y, Wu JA, Lowell T, Gu M, Yuan CS. Effects of Erkang, a modified formulation of Chinese folk medicine Shi-Quan-Da-Bu-Tang, on mice. J Ethnopharmacol. 1998;61: 153-159.
15. Kamiyama H, Takano S, Ishikawa E, Tsuboi K, Matsumura A. Anti-angiogenic and immunomodulatory effect of the herbal medicine "Juzen-taiho-to" on malignant glioma. Biol Pharm Bull. 2005;28: 2111-2116.
16. Nakamoto H, Mimura T, Honda N. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis. Hemodial Int. 2008;12(suppl 2):S9-S14.
17. Kaneko T, Chiba H, Horie N, et al. Effect of two different groups of Chinese medicines on nitric oxide production by mouse macrophage-like cells. In Vivo. 2004;18: 771-778.
18. Tagami K, Niwa K, Lian Z, Gao J, Mori H, Tamaya T. Preventive effect of Juzen-taiho-to on endometrial carcinogenesis in mice is based on Shimotsu-to constituent. Biol Pharm Bull. 2004;27: 156-161.
19. Saiki I. A Kampo medicine "Juzen-taiho-to"-prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull. 2000;23: 677-688.
20. Committee on Chinese Medicine and Pharmacy, Department of Health, Taiwan. Shi Quan Da Bu Tang. http://tcam.ccmp.gov.tw/meun-2-content.asp?aaa=104. Updated 2010. Accessed March 15, 2010.
21. Hisha H, Yamada H, Sakurai MH, et al. Isolation and identification of hematopoietic stem cell-stimulating substances from Kampo (Japanese herbal) medicine, Juzen-taiho-to. Blood. 1997;90: 1022-1030.
22. Ohnishi Y, Yasumizu R, Fan HX, et al. Effect of Juzen-taiho-to (TJ-48), traditional oriental medicine, on hematopoietic recovery from 5 cells with oleic acid and linolenic acid resulted in the radiation injury in mice. Exp Hematol. 1990;18: 18-22.
23. National Cancer Institute. Common Terminology Criteria for Adverse Events ver. 3.0. http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx. Updated 2004. Accessed March 15, 2010.
24. Crespi CM, Wong WK, Mishra SI. Using second-order generalized estimating equations to model heterogeneous intraclass correlation in cluster-randomized trials. Stat Med. 2009;28: 814-827.
25. Castagna L, Bramanti S, Levis A, et al. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol. 2010;21: 1482-1485.
26. Gerds A, Fox-Geiman M, Dawravoo K, et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2010;16: 678-685.
27. Rivera E, Erder MH, Moore TD, et al; Risk Model Study Group. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model. Cancer. 2003;98: 222-228.
28. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24: 3187-3205.
29. Kogure T, Ltoh K, Tatsumi T, et al. The effect of Juzen-taiho-to/TJ-48 on the expression of killer-cell immunoglobulin-like receptors (CD158a/b) on peripheral lymphocytes in vitro experiment. Phytomedicine. 2005;12: 327-332.
30. Fujiki K, Nakamura M, Matsuda T, et al. IL-12 and IL-18 induction and subsequent NKT activation effects of the Japanese botanical medicine Juzentaihoto. Int J Mol Sci. 2008;9:1142-1155.